Conclusion Midodrine is a short-acting vasopressor approved by the FDA in 1996 for
orthostatic hypotension. It belongs to the drug class alpha-1-receptor agonist which …

Shock is a state of decreased organ perfusion that is life-threatening and requires emergent
medical intervention [1]. As such, patients who present with shock are often managed in the …

Successful identification and characterisation of a titratable and safe oral agent that
consistently increases blood pressure carries a great deal of appeal and the promise of …

Midodrine is an oral agent which acts as a selective peripherally-acting α-receptor agonist.
Midodrine is a prodrug that is almost completely absorbed after oral administration and …

We are thankful to Riker and Gagnon for their comment [1] on our recently published MIDAS
trial [2]. Many intensivists would like to use midodrine to facilitate discharge from the …

Background Patients admitted to intensive care units (ICU) are often treated with intravenous
(IV) vasopressors. Persistent hypotension and dependence on IV vasopressors in otherwise …

Background Dialysis in patients with severe congestive heart failure and low blood pressure
is difficult even in a hospital setting. We retrospectively recorded the effects and usefulness …

PURPOSE: To study the safety and efficacy of Midodrine to treat hypotension in critically ill
patients. We hypothesized that patients would have higher mean arterial pressure (MAP) at …

The article focuses on the basic pharmacology and pharmacokinetics of midodrine to
answer questions on its contraindications. Midodrine is a prodrug that is absorbed from the …

DISCUSSION: Midodrine is an oral alpha 1 agonist indicated to treat orthostatic
hypotension. Off-label midodrine in the ICU is used to decrease or replace IV vasopressors …